Schopohl J, Mehltretter G, von Zumbusch R, Eversmann T, von Werder K
Medizinische Klinik, Klinikum Innenstadt, München, Germany.
Fertil Steril. 1991 Dec;56(6):1143-50.
To compare pulsatile gonadotropin-releasing hormone (GnRH) therapy with gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism.
Prospective study. Patients had free choice between the two forms of therapy.
Patients were treated on an outpatient basis in our department.
Eighteen patients of matched age (mean [+/- SD] age: 21.1 +/- 3.0 years and 23.6 +/- 7.3 years) and similar testicular volume were treated in each group.
Pulsatile GnRH therapy was started with 4 micrograms GnRH subcutaneously every 2 hours using a portable pump and gonadotropin therapy with 3 x 2,500 IU human chorionic gonadotropin (hCG) weekly injected intramuscularly. After 8 to 12 weeks of hCG treatment, 150 IU human menopausal gonadotropin two to four times weekly were added.
Testosterone (T) and estradiol (E2) levels increased significantly higher (T: P less than 0.03; E2; P less than 0.001) in the gonadotropin group than in the GnRH group (T: 22.5 +/- 8.1 versus 16.8 +/- 5.5 nmol/L; E2: 150 +/- 70 versus 88. +/- 59 pmol/L). Five patients developed gynecomastia during gonadotropin therapy. The rise of testicular volume was significantly more pronounced (P less than 0.001) in the GnRH group (delta testicular volume = 8.1 +/- 2.0 mL) than in the gonadotropin group (delta testicular volume = 4.8 +/- 1.8 mL). Ten patients of the GnRH and 8 of the gonadotropin group had positive sperm counts, ranging from 1.5 to 26 x 10(6) spermatozoa/mL. The latter was achieved more rapidly in the GnRH group (12 +/- 1.6 versus 20 +/- 2.3 months: P less than 0.02).
Endocrine and exocrine testicular function can be normalized by both forms of therapy. Gonadotropin therapy has more side effects. Gonadotropin-releasing hormone leads to a higher testicular volume and a more rapid initiation of spermatogenesis compared with gonadotropin therapy.
比较脉冲式促性腺激素释放激素(GnRH)疗法与促性腺激素疗法对特发性下丘脑性性腺功能减退男性患者的疗效。
前瞻性研究。患者可自由选择两种治疗方式。
患者在我院门诊接受治疗。
每组治疗18例年龄匹配(平均[±标准差]年龄:分别为21.1±3.0岁和23.6±7.3岁)且睾丸体积相似的患者。
脉冲式GnRH疗法起始剂量为每2小时皮下注射4微克GnRH,使用便携式泵给药;促性腺激素疗法为每周肌肉注射3次,每次2500国际单位人绒毛膜促性腺激素(hCG)。hCG治疗8至12周后,每周添加150国际单位人绝经期促性腺激素,给药2至4次。
促性腺激素组的睾酮(T)和雌二醇(E2)水平升高幅度显著高于GnRH组(T:P<0.03;E2:P<0.001)(T:22.5±8.1对16.8±5.5纳摩尔/升;E2:150±70对88±59皮摩尔/升)。5例患者在促性腺激素治疗期间出现乳腺增生。GnRH组睾丸体积的增加更为显著(P<0.001)(睾丸体积变化量=8.1±2.0毫升),高于促性腺激素组(睾丸体积变化量=4.8±1.8毫升)。GnRH组10例患者和促性腺激素组8例患者精子计数为阳性,范围为1.5至26×10⁶个精子/毫升。GnRH组达到这一结果的时间更快(12±1.6对20±2.3个月:P<0.02)。
两种治疗方式均可使睾丸的内分泌和外分泌功能恢复正常。促性腺激素疗法副作用更多。与促性腺激素疗法相比,促性腺激素释放激素可使睾丸体积更大,精子发生启动更快。